Active surveillance versus radical treatment for favorable-risk localized prostate cancer

Current Treatment Options in Oncology

Volumn 7, Issue 5, 2006, Pages 355-362

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TRACE ELEMENT; VITAMIN;

BRACHYTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTERMETHOD COMPARISON; MALE; NORTH AMERICA; PATIENT MONITORING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 33748347263     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0003-z     Document Type: Review

References (32)

1. Sakr WA, Haas GP, Cassin BF, et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379-385.
2. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. CA Cancer J Clin 1993, 43:7-26.
3. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
4. Welch HG, Schwartz LM, Woloshin S: Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005, 97:1132-1137.
5. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224
6. McGregor M, Hanley JA, Boivin JF, et al.: Screening for prostate cancer: estimating the magnitude of over-detection. CMAJ 1998, 159:1368.
7. Etzioni R, Penson DF, Legler JM, et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94:981-990.
8. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
9. Tornblom M: Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122-129.
10. Albertsen PC, Hanley JA, Fine J: 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
11. Stamey TA, Freiha FS, McNeal JE, et al.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71:933-938.
12. Epstein JI, Walsh PC, Carmichael M, et al.: Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374.
13. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retro-pubic prostatectomy. Cancer 1993, 71:3582-3593.
14. Epstein JI, Carmichael M, Partin AW, et al.: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993, 149:1478-1481.
15. Epstein JI, Chan DW, Sokoll LJ, et al.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998, 160:2407-2411.
16. Goto Y, Ohori M, Arakawa A, et al.: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996, 156:1059-1063.
17. Kattan MW, Eastham JA, Wheeler TM, et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003, 170:1792-1797.
18. Augustin H, Hammerer PC, Graefen M, et al.: Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003, 43:455-460.
19. Noguchi M, Stamey TA, McNeal JE, et al.: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001, 166:104-109; discussion 109-110.
20. Irwin MB, Trapasso JG: Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994, 44:862-867; discussion 867-868.
21. Cupp MR, Bostwick DG, Myers RP, Oesterling JE: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995, 153:1543-1548.
22. Anast JW, Andriole GL, Bismar TA, et al.: Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004, 64:544-550.
23. Choo R, DeBoer G, Klotz L, et al.: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001, 50:615-620.
24. Kakehi Y. PSA DT in Japanese active surveillance cohort (48 patients). Jpn J Clin Oncol 2003, 33:1-5.
25. Egawa S, Arai Y, Tobisu K, et al.: Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000, 3:269-274.
26. McLaren DB, McKenzie M, Duncan G, et al.: Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998, 82:342-348.
27. D'Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-135.
28. Choo R, Klotz L, Danjoux C, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664-1669.
29. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005, 23:8165-8169.
30. Klotz L: Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 2005, 12:21-24.
31. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
32. Steineck G, Helgesen F. Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790-796.